Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Transcept Aims To Refile Intermezzo Insomnia NDA In Late Q4 With Highway Driving Data

Mar 25 2010

• By The Pink Sheet Daily

Related Content

Takeda's Rozerem Substance Abuse/Toxicity Claims Draw FDA Rebuke

Mar 24 2010

Somaxon's Silenor Gains An FDA Approval, But Can The Pharma Afford A Launch?

Mar 18 2010

Transcept's Intermezzo Yields To FDA Concerns Over Residual Side Effects

Oct 29 2009

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window